Pharmacogenetics: From Bench to Byte— An Update of Guidelines

By J. Swen, M. Nijenhuis, A. Boer, L. Grandia, A. M. D. Zee, H. Mulder, G. Rongen, R. Schaik, T. Schalekamp, D. Touw and 4 more. Clinical pharmacology and therapy, 2011

1,042 citations recorded by the source corpus.

Subfields: Molecular Biology, Pediatrics, Perinatology and Child Health, Pharmacology

View Paper: https://www.semanticscholar.org/paper/497c6f31e97cf02b48c6e7ee4e06be754ff9dbb8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Caroline F. Thorn
2. Teri E. Klein
3. Russ B. Altman
4. Wen Torng
5. Yuan Luo

In Pediatrics, Perinatology and Child Health

1. Caroline F. Thorn
2. Russ B. Altman
3. Teri E. Klein

In Pharmacology

1. Caroline F. Thorn
2. Russ B. Altman
3. Teri E. Klein

Citations in the corpus

• PharmGKB: The Pharmacogenomics Knowledge Base (2013, methodology): “The clinical pharmacogenomics tab displays any dosing guidelines involving the gene published by CPIC (the Clinical Pharmacogenomics Implementation Consortium) [7] and the Royal Dutch Pharmacogenetics Working Group [8].”
• Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (2017, background): “A 25% reduction of the recommended dose may be considered for CYP2D6 intermediate metabolizers (27).”